Key facts
- It has raised $8.3M; the latest was Seed Round ($8.3M) in Mar 2026.
- Notable investors include Delin Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Swarm Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Swarm Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Swarm Oncology
Operator of a cell therapy platform intended to treat metastatic solid tumors. The company offers in vivo priming, patient screening, correct cell isolation, and expansion without exhaustion, enabling clients to develop autologous therapies that are safe, specific, durable, and applicable to patients with weakened immune systems.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 10
- Website
- swarmoncology.bio/
- Ownership
- Privately Held (backing)
Swarm Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Swarm Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Swarm Oncology in its N-PORT filings yet. We sweep new filings monthly.